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Abstract
Background:  Post-transplant lymphoproliferative disorder (PTLD) is a complication of solid
organ and allogeneic hematopoietic stem cell transplantation (HSCT); following autologous HSCT
only rare cases of PTLD have been reported.
Here, a case of Hodgkin's disease (HD), as unusual presentation of PTLD after autologous HSCT
for malignant glioma is described.
Case presentation: 60-years old man affected by cerebral anaplastic astrocytoma underwent
subtotal neurosurgical excision and subsequent high-dose chemotherapy followed by autologous
HSCT. During the post HSCT course, cranial irradiation and corticosteroids were administered as
completion of therapeutic program.
At day +105 after HSCT, the patient developed HD, nodular sclerosis type, with polymorphic HD-
like skin infiltration.
Conclusion: The clinical and pathological findings were consistent with the diagnosis of PTLD.
Background
Post-transplant lymphoproliferative disorders (PTLDs)
are severe complications that occur in solid organ and all-
ogeneic hematopoietic cell transplantation (HSCT), and
their incidence ranges from 1% to 20% [1].
Most PTLDs are classified as B-cell (rarely T-cell) PTLD,
often related to Epstein-Barr virus (EBV) infection. Some-
times, after allogeneic HSCT, non Hodgkin lymphoma
(NHL) or Hodgkin's disease (HD) have been described as
PTLDs [2].
Herein, we report the first case of HD, as unusual presen-
tation of PTLD, in a patient undergoing high dose sequen-
tial chemotherapy and autologous HSCT for malignant
glioma.
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Case presentation
A 60-year-old male was diagnosed with anaplastic astrocy-
toma involving the left parietal and temporal lobes. The
patient underwent surgical resection with subsequent
magnetic resonance imaging (MRI)-proven complete
excision.
In the context of a clinical trial, exploring the role of high-
dose chemo-radiotherapy in malignant glioma, the
patient underwent high dose sequential chemotherapy
consisting of cyclophosphamide 7 g/m2 plus rhG-CSF (5
µg/kbw) and hematopoietic cells harvest, followed by
methotrexate 8 g/m2 and thiotepa 900 mg/m2. Autolo-
gous unfractionated hematopoietic stem cells were
administered at doses of 7.5 × 106/kg CD34+ cells and the
patient experienced an uncomplicated hematological
recovery within 10 days.
One month later, the patient received 70-Gy of fractioned
whole-brain irradiation, and steroids (dexamethasone 8
mg i.v. bid) were administered for 2 months and than
tapered at the end of radiotherapy.
On day +105 he was hospitalized because of the occur-
rence of right hilum lymphoadenopathy associated with
cutaneous lesions, as limited erythematous plaques, with
well-demarcated margins and scalings.
Surgical nodes and skin excision showed the presence of
HD, nodular sclerosis type, with atypical HD-like ele-
ments, infiltrating the skin. The staging evaluation, per-
formed by CT scan of abdomen and thorax and bone
marrow biopsy, was negative for distant involvement
(stage IA) and no treatment was administered after radical
surgery.
Eight months after HSCT, the malignant glioma relapsed
and the patient received 2 cycles of carmustine (240 mg/
m2 i.v. q.6 weeks) without clinical benefit, followed by
palliative neurosurgical subtotal excision. The steroids
treatment was resumed (dexamethasone 4 mg, daily) and
chronically administered as supportive care.
Six months later, histological-confirmed HD relapse
occurred as bilateral hilum lymphoadenopaty. Because of
deteriorated neurological clinical conditions, the patient
declined any further treatment and died 2 months later
for progressive glioma.
Lymph node and skin biopsies were fixed in 10% buffered
formalin and paraffin embedded. Micron sections were
then prepared and stained with hematoxylin and eosin.
Paraffin section immunohistochemical stains were per-
formed using a biotin-streptavidin technique. The lymph
node structure and the skin biopsy were diffusely effaced
by a growth consisting of polymorphic features of small T-
cell-rich B cell lymphoma/HD-like, and typical Hodgkin's
and Reed-Sternberg cells (HRSCs), nodular sclerosis type
with limited areas of lymphocyte depletion (REAL) (Fig. 1
and 2). At immunohistochemistry, HRSCs expressed the
following molecules: CD30+, CD43+, CD15+/-, CD3+/-;
and were negative for EMA, ALK and CD20.
EBV latent membrane protein (LMP-1) was weakly posi-
tive at HRSCs immunohistochemistry, but EBV-DNA
determination by PCR [3] performed in multiple node
biopsy fragments and in peripheral blood mononuclear
cells (PBMC) yielded negative results.
According to the clinical, histological and immunohisto-
chemical findings, HD consistent with non EBV-associ-
ated PTLD was diagnosed.
Conclusion
Usually reported after allogeneic transplantation, PTLD is
a rare event after autologous HCT (Table 1). In most of
cases, the onset is within the first in 3 months after HCT
(vs 6 months in allogeneic setting), during the time of
immunosuppession.
Although HD is not the commonest form of PTLD mani-
festation, several reports classified HD as a possible poly-
morphic aspect of the post-transplant malignancies, and
HD-like lesions are included among the distinctive cate-
gories of PTLD [4].
The early time of onset after HCT and the presence of risk
factors for immunological impairment are considered
critical for distinguishing PTLD from classic form of HD
occurring later in the post-transplant period [5].
EBV appears to be the major contributor to the pathogen-
esis of PTLD. Uncertain is the promoting role of EBV in
EBV-negative PTLDs, while a possible involvement of EBV
infection in HD or T-cell PTLD appears controversial.
Beside the speculative interest on the pathogenetic mech-
anisms of the different presentations of PTLD, EBV-nega-
tive forms of the disease pose important questions on
diagnosis and treatment of PTLD.
In this case, the patient presented a post-transplant EBV-
negative HD; the treatment administered for malignat gli-
oma, consisting of immuno-suppressive procedures (HDS
with autologous HCT, radiotherapy and steroids), played
a role in immunologic derailment and exposed the
patient to an high risk of PTLD.
In our opinion, the rapid onset of HD after HSCT (+105
day), the clinical and the histopathological characteristicsBMC Cancer 2005, 5:109 http://www.biomedcentral.com/1471-2407/5/109
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are consistent with a rare presentation of HD as EBV-neg-
ative PTLD. Surveillance for PTLD should be considered
also in patients affected by solid malignancies receiving
autologous HSCT.
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H&E stained sections of lymph node (fig.1) and skin (fig.2) excision in which the diagnostic Reed-Sternberg cell support the 
diagnosis of Hodgkin disease.
Table 1: PTLDs after autologous HCT in adults
Source (N° of cases) Disease HCT PTLD (days) PTLD (type)
Young 1989[6] (2) T cell LL T cell purged 48/31 NHL polymorphic B cell
Chao 1993[7] (1) FML B cell purged 52 NHL monomorphic B cell
Shephered 1995[8] (1) CML Unmanipulated 43 NHL polymorphic B cell
Briz 1997[9] (1) T cell ALL T cell purged 81 NHL monomorphic B cell
Hauke 1998[10] (2) HD/FLL Unmanipulated 87/38 NHL polymorphic B cell
Peniket 1998[11] (1) MM CD34+ selected 80 NHL monomorphic B cell
Lohrish 2000 [12] (1) BL Unmanipulated 39 NHL polymorphic B cell
Yufu 2000 [13] (1) HD Unmanipulated 900 T cell PTLD
Jenkins 2002 [14] (3) 2MM/1NHL CD34+ selected/
Unmanipulated
31/NA NHL polymorphic B cell
ALL: acute lymphoblastic leukemia; CML: chronic myelogenous leukemia; FML: follicular mixed small cleaved and large lymphoma; FLL: follicular 
large cell lymphoma; LCL: large cell lymphoma; LL: lymphoblastic lymphoma; BL: Burkitt's lymphoma; HD: hodgkin disease; NHL: non hodgkin 
lymphoma; MM: multiple myeloma PTLD: post transplant lymphoproliferative disorder; HCT: hematopoietic cell transplantation; NA: not available.Publish with BioMed Central    and   every 
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